Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853611 | 0.88 | ALDH1A1 (0.64) | ALDH1A1CYP2A6HSD17B10ALDH5A1ABAT | |
| SCHEMBL10306547 | 0.85 | — | — | |
| SCHEMBL2964 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL2831797 | 0.83 | PTGS1 (0.52) | ALDH1A1PTGS1KMT2ACYP2A6HSD17B10 | |
| SCHEMBL10031894 | 0.81 | NFE2L2 (0.58) | PTGS1HSD11B1NFE2L2 | |
| SCHEMBL29572439 | 0.81 | MAOA (0.46) | ALDH1A1KMT2ACYP2A6MEN1CYP1A2 | |
| SCHEMBL3966352 | 0.81 | MAOA (0.46) | ALDH1A1KMT2ACYP2A6MEN1CYP1A2 | |
| SCHEMBL576260 | 0.80 | MEN1 (0.48) | ALDH1A1KMT2AMEN1L3MBTL1CYP1A2 | |
| SCHEMBL17508272 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CYP2A6HSD17B10ALDH5A1ABAT | |
| SCHEMBL1466194 | 0.79 | KCNQ3 (0.40) | ALDH1A1KMT2AMEN1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986540-B1 | THE USE OF CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2005-02-16 | — | — | EP | claimed |
| US-6696442-B2 | THERAPY OF DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES, WHICH ACT AS BLOCKERS OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2004-02-24 | — | — | US | claimed |
| US-RE38425-E1 | ANTICONVULSANTS ADMINISTERED ORALLLY | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES, INC. (CA) | 2004-02-10 | — | — | US | claimed |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | EURO-CELTIQUES S.A. | 2003-12-04 | — | — | US | claimed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | claimed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | claimed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | claimed |
| EP-0836591-B1 | SEMICARBAZONES HAVING CNS ACTIVITY AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | UNIV SASKATCHEWAN (CA) | 2001-09-26 | — | — | EP | claimed |
| US-5741818-A | ANTICONVULSANTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1998-04-21 | — | — | US | claimed |
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-8394836-B2 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| EP-2327693-A1 | Indoles and their therapeutic use | Pulmagen Therapeutics (Asthma) Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | GB005, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2229358-A1 | INDOLES AND THEIR THERAPEUTIC USE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-6696442-B2 | THERAPY OF DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES, WHICH ACT AS BLOCKERS OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2004-02-24 | — | — | US | disclosed |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | EURO-CELTIQUES S.A. | 2003-12-04 | — | — | US | disclosed |
| US-6638947-B2 | Blockers of sodium channels; treatment of neuronal damage following global and focal ischemia, treatment or prevention of neurodegenerative conditions, pain | EURO-CELTIQUE S.A. (LU) | 2003-10-28 | — | — | US | disclosed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | disclosed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | IDO2, IDO1, RORB | ALDH1A1 1047/4885PTGS1 235/4885KMT2A 2716/4885 |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | FPR3, HRH2, HRH4 | ALDH1A1 1510/4885PTGS1 580/4885KMT2A 3786/4885 |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885PTGS1 526/4885KMT2A 3400/4885 |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885PTGS1 526/4885KMT2A 3400/4885 |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, CBR1, ALDH1A2 | ALDH1A1 97/4885PTGS1 658/4885KMT2A 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.